Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thrush

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Thrush. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-004504-36 Sponsor Protocol Number: 801-00 Start Date*: 2005-12-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.
    Medical condition: Candidiasis (invasive)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10007152 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) IT (Completed) PT (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-006409-18 Sponsor Protocol Number: 9463-EC-0002 Start Date*: 2010-02-09
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, D...
    Medical condition: Invasive Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007152 Candidiasis LLT
    12.1 10007162 Candidiasis of the intestine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) BE (Completed) GR (Completed) DE (Completed) FR (Completed) FI (Completed) IT (Completed) GB (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015159-26 Sponsor Protocol Number: UKW-Inf-001 Start Date*: 2011-03-14
    Sponsor Name:Universitaetsklinikum Wuerzburg
    Full Title: UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.
    Medical condition: Prophylaxis of invasive fungal infection, including life-threatening aspergillosis and candidiasis, is investigated in the study. Patient with acute myeloid leukemia or acute lymphatic leukemia wil...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003488 Aspergillosis PT
    12.1 10042941 Systemic fungal infection NOS LLT
    12.1 10007152 Candidiasis LLT
    12.1 10036898 Prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001270-26 Sponsor Protocol Number: VMT-VT-1161-CL-012 Start Date*: 2018-12-12
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-001269-18 Sponsor Protocol Number: VMT-VT-1161-CL-011 Start Date*: 2019-03-13
    Sponsor Name:Mycovia Pharmaceuticals, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BG (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000371-32 Sponsor Protocol Number: 13-02/AM-MG Start Date*: 2014-10-06
    Sponsor Name:Dermapharm AG
    Full Title: Randomised, double-blind, vehicle controlled trial comparing Amphotericin B 100.000 I.E./g oral gel vs. Ampho-Moronal® suspension vs. modified vehicle to suspension in adult patients with oropharyn...
    Medical condition: Oropharyngeal candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10050346 Oropharyngeal candidiasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001360-31 Sponsor Protocol Number: CKPV/21 Start Date*: 2005-07-04
    Sponsor Name:ABIOGEN PHARMA
    Full Title: A multicenter, randomised, double- blind, between-patient, dose finding study to assess the safety, tolerability and efficacy of three different dosages (500, 1000 and 2000 mcg/g) of ABIO 12/01 gel...
    Medical condition: VULVOVAGINAL CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046898 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003951-18 Sponsor Protocol Number: WSA-CS-008 Start Date*: 2007-05-29
    Sponsor Name:Astellas Global Pharma Development, Inc.
    Full Title: A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of candidemia and other invasive Ca...
    Medical condition: Treatment of Candidemia and other invasive Candida infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002600-40 Sponsor Protocol Number: SCY-078-304 Start Date*: 2020-01-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects with Recurrent Vulvova...
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-012848-16 Sponsor Protocol Number: A1501085 Start Date*: 2010-04-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH...
    Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10060573 Candidemia LLT
    14.1 10021881 - Infections and infestations 10064954 Invasive candidiasis LLT
    14.1 10021881 - Infections and infestations 10007161 Candidiasis of the esophagus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-000718-63 Sponsor Protocol Number: 13071 Start Date*: 2008-09-02
    Sponsor Name:Bayer Consumer Care AG
    Full Title: An investigator-blinded, active-controlled phase 3 study to prove the non-inferior efficacy of a Clotrimazole ovule (500 mg) versus a Clotrimazole vaginal tablet (500 mg) in vaginal candidiasis
    Medical condition: vaginal candidiasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046898 Vaginal candidiasis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002480-26 Sponsor Protocol Number: PRO_2013-02 Start Date*: 2014-10-27
    Sponsor Name:BIOSE
    Full Title: Study of the efficacy and safety of treatment with total freeze-dried culture of Lcr Regenerans® administered intravaginally in the prevention of recurrent vulvovaginal candidiasis. International, ...
    Medical condition: Recurrent vulvo-vaginal candidiasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004268-21 Sponsor Protocol Number: ProF-001_Phase_IIa Start Date*: 2017-03-23
    Sponsor Name:Profem GmbH
    Full Title: A phase IIa randomized, active-controlled, double-blind, dose-escalation study in patients with vulvovaginal candidiasis to evaluate clinical efficacy, safety and tolerability and dose response rel...
    Medical condition: Vulvovaginal candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004492-12 Sponsor Protocol Number: SCY-078-306 Start Date*: 2019-06-05
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects with Acute Vulvovaginal Candid...
    Medical condition: Acute Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016655-21 Sponsor Protocol Number: P-090756-01 Start Date*: 2010-04-30
    Sponsor Name:Ferrer Internacional, S.A
    Full Title: A Multi-Centre, Randomized, Placebo-controlled, Parallel-Group, Double-Blinded Study to Compare the Therapeutic Efficacy, Safety and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitra...
    Medical condition: Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047784 Vulvovaginal candidiasis PT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) FR (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003010-12 Sponsor Protocol Number: APHP180600 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: «Efficacy of Fluticasone Propionate associated with Salmeterol using inhalation chamber versus placebo to improve the respiratory function in children over six years of age who underwent allogeneic...
    Medical condition: Bronchiolitis Obliterative Syndrome after hematopoietic stem cell transplantation (HSCT). .
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004698-39 Sponsor Protocol Number: 1188.31 Start Date*: 2006-02-03
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily...
    Medical condition: This randomized, placebo-controlled, double-blind trial will be conducted in HIV-1 infected patients who have experienced virological failure with at least one NNRTI-based HAART regimen. The treatm...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002068-29 Sponsor Protocol Number: 1-09-09-2012 Start Date*: 2012-12-03
    Sponsor Name:Jan Stener Joergensen
    Full Title: Antibiotic Prophylaxis and Intervention for Postpartum Infections following Caesarean Section
    Medical condition: Sub-study 1: women delivering a child by caesarean section Sub-study 2: Women, who are hospitalized at the obstetrical ward for reoperation because of superficial or deep infection or haematoma...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000925-27 Sponsor Protocol Number: ProF-001_Phase_IIb/III Start Date*: 2019-08-27
    Sponsor Name:Profem GmbH
    Full Title: A phase IIb/III, parallel-arm, randomized, active-controlled, double-blind, double-dummy, study in patients with recurrent vulvovaginal candidiasis to compare the clinical efficacy, safety and tole...
    Medical condition: recurrent vulvovaginal candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021502-38 Sponsor Protocol Number: LO-10-02 Start Date*: 2011-01-25
    Sponsor Name:Christine Fromer Stiftung
    Full Title: STUDIE ZUR MESSUNG DER VAGINALEN INTERLEUKINE BEI PATIENTINNEN MIT ZERVIKALEN NEOPLASIEN (CIN 1-3) ODER CHRONISCHER CANDIDIASIS VAGINALIS UNTER BEHANDLUNG MIT 4PHENYL-BUTYRATE
    Medical condition: Patienten mit diagnostizierter cervikaler Neoplasie (CIN1-3) oder chronisch - rezidivierender Vaginalcandidiasis
    Disease: Version SOC Term Classification Code Term Level
    13.0 10008290 LLT
    13.0 10046898 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA